Nyxoah SA
NASDAQ · us_market
No AI insight generated yet for this ticker.
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | -0.44 | — | — |
| 2026-03-19 | -0.55 | -0.59 | -6.62% |
| 2025-11-13 | -0.56 | -0.63 | -11.78% |
| 2025-08-18 | -0.57 | -0.55 | +3.23% |
| 2025-05-14 | -0.50 | -0.60 | -20.03% |
| 2025-03-13 | -0.44 | -0.46 | -5.61% |
| 2024-11-06 | -0.45 | -0.50 | -9.59% |
| 2024-08-05 | -0.41 | -0.43 | -5.21% |
| 2024-05-14 | -0.41 | -0.41 | -1.77% |
| 2024-03-05 | -0.40 | -0.38 | +5.49% |
| 2023-11-08 | -0.43 | -0.27 | +38.62% |
| 2023-08-08 | -0.41 | -0.45 | -8.36% |
| 2023-05-16 | -0.34 | -0.46 | -36.66% |
| 2023-03-22 | -0.29 | -0.51 | -74.98% |
| 2022-11-08 | -0.33 | -0.24 | +26.26% |
| 2022-11-07 | -0.24 | -0.21 | +12.50% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NYXH | -0.67% | -20.53% | -35.22% | -61.05% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.64% | -15.90% | -31.77% | -73.73% |